According to Acumen Research and Consulting, the global scleroderma therapeutics market is forecasted to grow at striking CAGR around 6.4% over the forecast time frame and reach around US$ 3.8 billion by 2026.
It is an autoimmune rheumatic condition which causes the skin and connective tissues to get chronically hardened and tightened. However, it includes overproduction of collagen. The exact cause of Scleroderma is not known. Inner bodies such as blood vessels, heart, lungs, belly, and kidney may suffer harm. Scleroderma incidents in females are four times higher than in males. In addition, starting between 30 and 50 years is more frequent.
The elevated effect on scleroderma diagnostics and on the therapy industry of divers is the increased incidence of scleroderma and the increased incidence of genetic mutations combined with dramatic environmental modifications. The incidence of systemic scleroderma is approximately 35 instances per 1 million adults according to international reports from Japan and Britain. Four times more women than males are susceptible to systemic scleroderma. Furthermore, this market is anticipated to serve as future growth possibilities if high unsatisfied medical demands and the subsequent introduction of fresh products are met.
The report provides analysis of global Anatomic Pathology market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.
The market is motivated primarily by the labeling of drugs for its symptoms such as rheumatoid arthritis that are approved. The absence of curative therapies and the elevated incidence of off-label drug use are factors which stimulate interest in the markets for rare diseases.
The development of targeted biologics and tiny molecular combination therapies is anticipated to be fuel. The market is also anticipated to be driven by increased scleroderma and the increasing incidence of genetic mutations combined with dramatic environmental modifications.
Furthermore, growing available revenue, allowing for increased expenditure ability and the existence of a well-defined legislative structure to support efficient therapy development in advanced region fuel market development. In addition, the development of premium curatives undergoing clinical development will increase market growth over the forecast era. Additional approvals will also enhance development for current therapy alternatives.
This disease involves a broad variety of drug classes prescribed for first and second line treatment. The disease is correlated with comorbidity. Among the signs, the highest possible sales were achieved with pulmonary arterial hypertension (PAH). More than one drug class and several branded drugs form part of the drugs for this comorbidity. In addition, both authorized medicines are used to target PAH on this market, namely bosentan and iloprost. Increased Scleroderma incidence mainly drives development on the market. Scleroderma is a disease of long duration that demands a daily dose of medicines. In addition, the scleroderma diagnostics and therapeutics market is projected to raise awareness of preventive health care and boost the disposable income among the population. In addition, strict public regulations, adverse drug effects, elevated healthcare costs and Scleroderma diagnostic tests are key obstacles to the development of the industry. Ongoing R&D is expected to generate fresh possibilities during the forecast era in scleroderma diagnosis and therapeutics.
Drug Clas Stance
On the basis of drug class, the market is segmented into prostacyclin analogues, Phosphodiesterase 5 Inhibitors-PHA, calcium channel blockers, analgesics, immunosuppressors, endothelin receptor antagonists, and others. A wide variety of drug classes are prescribed for symptomatic relief without a curative treatment for this disease. Immunosuppressants are of prominence because they include several biological products from well-known players like Roche. Small molecule immunosuppressants and biologics are a increasing sector with several scleroderma pipeline medicines. In the forecast period classified under "other drug classes," new treatments, including Lenabasum and Ofev, are anticipated. PDE-5 drug class market inhibitors face headwinds as a result of Revatio's patent expiry that decreases income. ERAs continue to be focused as the drug class mainly includes branded therapies and is therefore highly effective in their use in the therapy of the indication. HIP.
Based on indication, the scleroderma therapeutics market is segmented into localized and systemic scleroderma. SSC-led symptoms and conditions, ranging from interstitial pulmonary disease to arterial pulmonary hypertension, are the signs for systemic scleroderma. The use of high-priced immunosuppressants represents most of systemic signs.
Local scleroderma is presently low, but is anticipated to develop during the forecast period, with Fibrocell's anticipated launch of first-class FCX-013 treatment. Fibrocell's FCX-013 retains the designation of orphan drug and quick track, which would be the first localized scleroderma gene treatment if approved. This therapy is intended to stop the fibrosis in the early phases. The first oral treatment of Lenabasum with the elevated curative capacity for diffuse systemic scleratic cutaneous diseases associated with a elevated co-morbidity burden is Corbus Pharmaceuticals.
Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The North America dominated the global market in 2018. The main driver of income is access to newly established immunosuppressant substances and a favourable scenario of reimbursement. Europe is traveling with less of an out - of-label treatments of scleroderma than the United States mainly because of the greater use of generics and biosimilars. Generics and OTC medicines are the basis of scleroderma treatment and its symptoms in developing countries. Although prices are being cut in Japan, fresh orphan therapies can be accessed more rapidly. Principally drivers of regional market growth are the presence of favourable public laws and programs of finance combined with elevated market penetrations. In addition, a wide range of clinical trials are anticipated to foster further market growth with the aim of boosting efficiency and development of fresh products in the region. Due to the big existence of unsatisfactory patient requirements and the subsequent increase, Asia Pacific became the fastest growing region. In addition, a positive public initiative is anticipated to stimulate market growth in Japan and Australia throughout the forecast period. In Latin America and the MEA areas there will be an expected increase in the number of biosimilar and generic immunosuppressants.
Market, By Drug Class
Market, By Indication
Market, By Geography
The market research study on “Scleroderma Therapeutics Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global scleroderma therapeutics market segments with market dynamics and their impact. The report also covers basic technology development policies.
It offers an assessment of the recent industry trends for each sub-segment between 2015 and 2026, and anticipates income development at worldwide, regional and nation levels. For this research, ARC segmented the worldwide Scleroderma Therapeutics market report on the grounds various segments.
Key Players & Strategies
Some of the key players are Active Biotech AB, Allergan, Inc., BioLineRx, Ltd., Bayer AG, Digna Biotech, F. Hoffmann-La Roche Ltd., Angion Biomedica Corp., GlaxoSmithKline plc, Corbus pharmaceuticals, Inc., S.L., Fibrocell Science, Inc. Daval International Ltd., Bristol-Myers Squibb Company and Dynavax Technologies Corporation. Competitive market dynamics arise through strategic initiatives, which include fusion and acquisitions, partnerships and joint ventures.
Small players, particularly in Asian emerging markets, also enter the market. However, the market penetration of fresh entrants will be reduced by strict legislative structure and high quality standards set by market leaders.
These players focus on development strategies like product portfolio expansion, combinations and purchases and promotional activities to enhance their presence in unexploited market economies around the world.
According to Acumen Research and Consulting, the scleroderma therapeutics market value is anticipated to be worth around US$ 3.8 billion in 2026.
The scleroderma therapeutics market is anticipated to grow over 6.4% CAGR during the forecast period 2019 to 2026.
North America held maximum share in 2018 for scleroderma therapeutics market.
Asia Pacific is projected to grow at a fast pace during forecast period in the scleroderma therapeutics market.
Active Biotech AB, Allergan, Inc., BioLineRx, Ltd., Bayer AG, Digna Biotech, F. Hoffmann-La Roche Ltd., Angion Biomedica Corp., and GlaxoSmithKline plc are the top players operating in the scleroderma therapeutics market.
Based on indication, the scleroderma therapeutics market is segmented into localized and systemic scleroderma.
On the basis of drug class, the market is segmented into prostacyclin analogues, Phosphodiesterase 5 Inhibitors-PHA, calcium channel blockers, analgesics, immunosuppressors, endothelin receptor antagonists, and others.